100
Views
18
CrossRef citations to date
0
Altmetric
Special Report

First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy

Pages 953-956 | Published online: 10 Jan 2014
 

Abstract

Viral replication and pathogenesis involves many cellular protein kinases, and many specific inhibitors of such kinase have been developed for the treatment of noninfectious diseases. As expected, such drugs have been repeatedly demonstrated to inhibit viral replication in cultured cells. Cellular protein kinases have thus been considered for several years as potentially valid targets for antiviral therapy. However, until recently there was no proof of such activity in vivo. The three papers discussed herein demonstrate that inhibitors of cellular protein kinases are indeed effective for the treatment of virus-induced disease in animal models and human clinical trials.

Acknowledgements

LMS is a CIHR New Investigator, an AHFMR Scholar and a Burroughs-Wellcome Fund (BWF) Investigator in the Pathogenesis of Infectious Disease. The studies in our lab are supported by CIHR operating budget grant MOP49551 and by the Burroughs-Wellcome Fund. Our laboratory was equipped with funds provided by the AHFMR and the Faculty of Medicine and Dentistry of the University of Alberta.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 866.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.